UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 8, 2017

IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	**0-27598**	**77-0210467**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

1212 Terra Bella Avenue
Mountain View, California 94043
(Address of principal executive offices, including zip code)

(650) 940-4700
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 8, 2017, IRIDEX Corporation (the "Company") posted presentation slides in PDF format to its website (http://www.iridex.com/) that the Company anticipates using in conferences and meetings with industry participants, investors and other third parties.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation slides posted on November 8, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRIDEX CORPORATION

By: /s/ William M. Moore
William M. Moore
President and Chief Executive Officer

Date: November 8, 2017

Exhibit 99.1

Investor Presentation

November 2017

IRIDEX®

Forward Looking Statements

Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make forward-looking statements regarding future events or the future performance of the Company.

We caution you that such statements are just predictions that involve risks and uncertainties, and that actual events or results could differ materially. We discuss a number of the risks in our business in detail in the Company's SEC reports, including our latest Form 10-K and our latest Form 10-Q.

IRIDEX

Investment Highlights

Underserved and Growing Patient Population

- 80M people with Glaucoma; 25M diagnosed
- Estimated 100M people with diabetes-related eye disease

Differentiated Laser Technology

- MicroPulse® Patented and Trademarked
- Significant data supports clinical and economic benefit

Recent Transformational Shift in Business Model

- Entering rapidly growing Glaucoma market
- Expanding focus on captive disposables business model

Established Revenue Base and Worldwide Customers

- Leverage and stability for future expansion
- Strong global brand built over 30 years

Source: Market Scope estimate as of 2015

IRIDEX

Our Focus: Sight-Threatening Eye Diseases

Retinal Disease

- Current focus on diabetic macular edema (DME), which is a common complication of diabetes and can lead to blindness

Treatment goal: *reduce retinal swelling; preserve/improve vision at a reduced cost*



Glaucoma

- Glaucoma is associated with high intra-ocular pressure (IOP)
- High IOP damages the optic nerve and is the leading cause of blindness for people over 60 years old

Treatment goal: *reduce IOP by increasing outflow or decreasing inflow of intraocular fluid; delay progression of disease; reduce cost*

IRIDEX

Shortcomings in the Treatment of Glaucoma and Retinal Disease

IRIDEX's MicroPulse® Laser Therapy delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye disease

PHARMACEUTICALS

- Requires continuous lifetime treatment
- High cost
- Significant compliance issue
- Side effects

LEGACY LASERS

- Lack durable outcomes
- Not repeatable
- Side effects

INVASIVE SURGERY

- High complication rate
- High failure rate
- Limited in scope
- Irreversible

IRIDEX

Our Proprietary MicroPulse® Laser Therapy

- Differentiated algorithm
- Clinically effective
- Allows tissue to cool between laser pulses, minimizing damage



Glaucoma Business Overview

IRIDEX

Glaucoma Macro Trends

80M
Estimated 80 million patients worldwide, 25M diagnosed

70+
Aging population; 50% of glaucoma patients are over age 70

$5B
Approx. $5B spent annually on pharmaceutical (~90%) and device treatments (~10%)

50%
Dire compliance issue - 50% of patients are not compliant at 1 year

Source: Market Scope estimate as of 2015

Shortcomings of Alternate Glaucoma Treatment Options

Prescription Eye Drops

- High non-compliance rates
- Complex dosing regimens
- Adverse side effects
- High, recurring costs

Legacy Lasers – SLT, ALT, MLT

- Effects dissipate over time
- Repeat procedures less effective

MIGS devices

- Limited to use in cataract surgery
- Incisional procedure with implant left behind
- Long term efficacy unclear

Traditional Surgery

- High complication rate
- High failure rate
- Limited long-term efficacy
- Significant post-operation patient management

IRIDEX

Cyclo G6™ Addresses Significant Unmet Need

- Safe
- Non-incisional
- Easy to perform
- Titratable
- Repeatable
- Durable
- Treats full range of disease
- Cost effective

IRIDEX

New Solutions Across the Continuum of Glaucoma Care

EYE DROPS | TRADITIONAL LASER | MIGS | INVASIVE SURGERY

EARLY STAGE | MODERATE STAGE | LATE STAGE | REFRACTORY

Cyclo G6™ System and associated probes

- Technology capability resides in the probe
- Low system cost
- Captive disposable probe business model

MicroPulse P3™ (MP3) Probe

G-Probe Illuminate

G-Probe™

MP3 Probe: Significant and Compelling Clinical Evidence

Consistent outcomes across broad group of independent physicians

Short-term Results

- 6 peer-reviewed publications
  - 220+ eyes treated
  - Patient follow up: 30 days to 18 months
  - IOP reduction: 20-50%
  - Reduction in eye drops
  - Limited adverse events
- 18 studies, clinical posters and presentations
  - 1,000+ eyes treated

Long-term Results

- Patient follow-up: 78 months
- IOP reduction: 43%
- Reduction in eye drops
- Limited adverse events
- Repeatable procedure: average 3.6 treatments per patients

Mechanism of Action

- Changes consistent with improved aqueous outflow
- Minimal tissue damage

Clinical references and sources available in the Supporting Material section of this presentation

IRIDEX

Growing Leadership and Validation in the Field

- **Reimbursement with permanent U.S. CPT code**
- **Growing list of relationships with prestigious institutions**
- **Increasing customers purchasing multiple systems**
- **Increasing KOL support around the world**
- **Expanding probe utilization**

UW Medicine Department of Ophthalmology
EMORY HEALTHCARE
AMSURG
KAISER PERMANENTE
Duke University School of Medicine
New York Eye and Ear Infirmary of Mount Sinai
WillsEye Hospital America's First World's Best
Tufts Medical Center
UCSF Medical Center
Stanford Medicine
IRIDEX

Business Evolution to Drive Long-Term Growth



Target G6 Installed Base Opportunity

U.S. Installed Base Opportunity:
5,000

- 5,000 ASCs
- 19,000 ophthalmologists
- 4.3M glaucoma patients

+

O.U.S. Installed Base Opportunity:
5,000

- 190,000 ophthalmologists
- 75.7M glaucoma patients

=

Total Global Installed Base Opportunity:
10,000

IRIDEX

Source: Company estimates

Target G6 Probe Market Opportunity



Strongest G6 candidates

- Compliance issue
- Desire non-invasive, durable, and cost-effective solution

Opportunity to treat patients 4-6 times during their glaucoma life

IRIDEX

Source: Market Scope estimates as of 2015 and Company estimates

Expanding Worldwide G6 Commercialization





*as of 3Q17

IRIDEX

Retinal Disease Business Overview

IRIDEX

Shortcomings of Alternate Treatment Options for DME

LEGACY LASERS (*less common*)

Provides long term vision stability but:

- Tissue Damage
- Risk of vision loss

PHARMACEUTICALS (*current standard of care*)

- Only provides short term vision stability
- Requires repeated eye injections (every ~six weeks)
  - Painful
  - Complications
- High cost
  - High financial cost to payers
  - High time burden to patients and physicians

IRIDEX

MicroPulse® Retina Laser Therapy Provides Significant Clinical and Economical Value Proposition

Legacy Laser

Pre-treatment



1 Year Post-treatment



Scarring clearly visible using legacy laser technology

MicroPulse Laser Therapy

Pre-treatment



1 Year Post-treatment



Scarring non-existent using MicroPulse

- No visible tissue damage
- Long-term vision stabilization
- Significantly lower cost: financial and treatment burden

IRIDEX

Established Customer Base and Broad Global Support

Substantial Clinical Evidence supports **MicroPulse®** for treatment of DME

Safety

- 10-year follow-up data proved no detectable retina damage

Efficacy

- Randomized controlled trials showed improved vision and improved retinal sensitivity
- Over 135 published studies

Efficiency

- More treatable patients
- Improved patient pass-through rates
- Reduce financial cost and treatment burden

Economics

- Using anti-VEGF and MicroPulse therapy may reduce treatment burden and costs

Established

- More than 1 million patients treated
- Over 1,000 systems sold
- More than 65 countries served

IRIDEX

Financial Snapshot as of Q3 2017

Revenue ($ in millions)

* 2015 revenue impacted by supply chain issues
**Revenue guidance as of November 2, 2017

9 Month YTD Revenue Mix



Balance Sheet ($ in millions)	
Cash	$22.8
Debt	$0.0

IRIDEX

Long-Term Financial Goals

- $100+M in revenues
- 65% recurring, 35% systems
- 55+% gross margin
- 15+% operating margin



Focused Execution to Achieve Goals

NEAR AND MID-TERM GOALS

- Expand US and International presence
- Improve design and processes to increase outsource production capacity
- Product enhancements to introduce new features and benefits

FUTURE PROGRAMS IN DEVELOPMENT

- Lower cost and improved reliability laser technologies
- New delivery modalities
- MicroPulse® technology for other eye diseases

IRIDEX

Thank You

IRIDEX

Supporting Material

IRIDEX

Video Resources

Video 1:
Summary of MicroPulse: Dr. Myers at AAO 2017



Video 2:
Cyclo G6 Laser System Technology

Video 3:
Transscleral Cyclophotocoagulation with Cyclo G6

Video 4:
Interview with Dr. Jacky Lee at ESCRS 2015

Video 5:
Media Release on New Treatments for Glaucoma (Chinese with English subtitles)

Video 6:
News Report Dr. Harris on IQ577 for MLT and MP3

IRIDEX

Compelling Clinical Evidence

NUHS Study – 33% IOP reduction at 18 months

MP3 Clinical Outcomes Summary at 18 Months

- 33% mean IOP reduction at 18 months
- Reduction in eye drops from mean of 2.1 to 1.3
- On average 1.3 treatments per patient with MP3 probe
- Procedure can be add-on therapy as well as monotherapy
- No adverse events



IRIDEX

Compelling Clinical Evidence

NUHS Follow-up Study – 43% IOP reduction at 78 months

MP3 Clinical Outcomes Summary at 78 Months

- 43% mean IOP reduction at 78 months
- Reduction in eye drops from mean of 1.8 to 1.1
- On average 3.6 treatments per patient with MP3 probe

IRIDEX

Compelling Clinical Evidence: Additional Studies Provide Consistent Outcomes

Dr. Robert Noecker MP3 Patient Case Series
Mean IOP (n=46)



Wills Eye Hospital MP3 Peer Reviewed Study
Mean IOP (n=19)



Wills Eye Hospital MP3 Peer Reviewed Study
Mean IOP (n=19)



Dr. Thomas John Patient Case Series
Mean IOP (n=20)

IRIDEX

Compelling Clinical Evidence:

Additional Studies Provide Consistent Outcomes

Drs. Thomas Samuelson and Mark Hansen, Minnesota Eye Consultants

Reviewed 119 procedures and concluded that *"MicroPulse is an effective, non-invasive treatment to lower IOP and is a viable option for all types of glaucoma at various stages."*

Doheny Eye Center UCLA, Dr. Brian Francis

43% IOP reduction @ approximately 2 months follow-up (N=20)

University of Missouri, Dr. Rohit Krishna

43% IOP reduction @ 6 months follow-up (N=30)

Wills Eye Hospital, Dr. Marlene Moster

50% IOP reduction @ an average of 7.5 months follow-up (N=78)

University of Washington, Dr. Murray Johnstone

"Clinically used MicroPulse parameters induce outflow system configuration changes generally associated with improved aqueous flow."

UCSF, Dr. Shan Lin

"No presence of suprachoroidal fluid or anatomical changes were found." The study concluded, *"MP-TCP is effective at lowering IOP in the majority of patients and appears safe without major complications."*

Yale University study

Study demonstrating minimal tissue disruption from MP3

Multi-Center Retrospective study

30% IOP reduction at three months

Nisha Chadha, MD; Cataract & Refractive Surgery Today; September 2017

-New Laser Therapies For Glaucoma-

"...MicroPulse technology offers a novel means of laser delivery that has been shown to be safe and effective..."

Matthew E. Emanuel, MD Glaucoma Journal; Aug 2017

-MicroPulse Cyclophotocoagulation: Initial Results in Refractory Glaucoma-

"...The out comes of our study are promising with good evidence of the IOP-lowering effects of MP-TSCPC and decreased need for ocular antihypertensive medications postlaser at 6 months"..."

Shan Lin, MD UCSF

-Micropulse transderal diode laser cyclophotocoagulation: Mid to long term results-

"MicroPulse TCP is effective in lowering IOP in the majority of patients in this study in a mid-long term follow up, and appears safe with no major complications".

IRIDEX

Clinical Data References

- Clin Experiment Ophthalmol 2010;38(3):266-72
- EGS abstract, Prague, Czech Republic, June 19-22, 2016
- ARVO Abstract, Baltimore, Maryland, May 7-11, 2016
- Lasers Medical Science (2016)31:393-396, DOI 10.1007/s10103-015-1856-9
- Journal of Clinical & Experimental Ophthalmology, December 2016
- ASCRS Paper Presentation, Los Angeles, CA, May 2017
- ARVO Abstract, Baltimore, MD, May 2017
- AGS Abstract, Fort Lauderdale, FL, March 2016
- AGS Abstract, San Diego, CA, February 2015

IRIDEX


IRIDEX